The relationship of statins to rhabdomyolysis, malignancy, and hepatic toxicity: Evidence from clinical trials

Current Atherosclerosis Reports

Volumn 11, Issue 2, 2009, Pages 100-104

  Alsheikh Ali, Alawi A ^a   Karas, Richard H ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

AORTA STENOSIS; ARTICLE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HEART INFARCTION; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MUSCLE INJURY; NONHUMAN; OUTCOME ASSESSMENT; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; NEOPLASMS; RHABDOMYOLYSIS;

EID: 60849096661     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-009-0016-8     Document Type: Article

References (24)

1. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110: 227-239.
2. Baigent C, Keech A, Kearney PM, et al.: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366: 1267-1278.
3. Ridker PM, Cannon CP, Morrow D, et al.: C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005, 352: 20-28.
4. Ridker PM, Morrow DA, Rose LM, et al.: Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005, 45: 1644-1648.
5. Corti R, Fuster V, Fayad ZA, et al.: Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: A prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am Coll Cardiol 2005, 46: 106-112.
6. Robinson JG, Smith B, Maheshwari N, Schrott H: Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005, 46: 1855-1862.
7. Staffa JA, Chang J, Green L: Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002, 346: 539-540.
8. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH: The safety of rosuvastatin as used in common clinical practice: A postmarketing analysis. Circulation 2005, 111: 3051-3057.
9. Jacobs D, Blackburn H, Higgins M, et al.: Report of the Conference on Low Blood Cholesterol: Mortality associations. Circulation 1992, 86: 1046-1060.
10. Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH: Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials. J Am Coll Cardiol 2007, 50: 409-418.
11. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al.: ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002, 106: 1024-1028.
12. Thompson PD, Clarkson P, Karas RH: Statin-associated myopathy. JAMA 2003, 289: 1681-1690.
13. The SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med 2008, 359: 789-799.
14. Newman TB, Hulley SB: Carcinogenicity of lipid-lowering drugs. JAMA 1996, 275: 55-60.
15. Bjerre LM, LeLorier J: Do statins cause cancer? A metaanalysis of large randomized clinical trials. Am J Med 2001, 110: 716-723.
16. Dale KM, Coleman CIA Henyan NN, et al.: Statins and cancer risk: a meta-analysis. JAMA 2006, 295: 74-80.
17. Alsheikh-Ali AA, Trikalinos TA, Kent DM, Karas RH: Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol 2008, 52: 1141-1147.
18. Trikalinos TA, Ioannidis JP: Predictive modeling and heterogeneity of baseline risk in meta-analysis of individual patient data. J Clin Epidemiol 2001, 54: 245-252.
19. Mudd JO, Borlaug BA, Johnston PV, et al.: Beyond low-density lipoprotein cholesterol: Defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 2007, 50: 1735-1741.
20. Demierre MF, Higgins PD, Gruber SB, et al.: Statins and cancer prevention. Nat Rev 2005, 5: 930-942.
21. Rossebo AB, Pedersen TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359: 1343-1356.
22. Peto R, Emberson J, Landray M, et al.: Analyses of cancer data from three ezetimibe trials. N Engl J Med 2008, 359: 1357-1366.
23. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350: 1495-1504.
24. Feinleib M: Summary of a workshop on cholesterol and noncardiovascular disease mortality. Prevent Med 1982, 11: 360-367.